A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

ASP1570

Oral tablet

DRUG

pembrolizumab

Intravenous Infusion

DRUG

Trifluridine + Tipiracil

Oral Administration

DRUG

Bevacizumab

Intravenous Infusion

DRUG

Docetaxel

Intravenous Infusion

DRUG

Oxaliplatin

Intravenous Infusion

DRUG

Leucovorin

Intravenous Infusion

DRUG

5-Fluorouracil

Intravenous Infusion

DRUG

Irinotecan

Intravenous Infusion

DRUG

Pemetrexed

Intravenous Infusion

DRUG

Carboplatin

Intravenous Infusion

Trial Locations (41)

10032

RECRUITING

Columbia University, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

20817

RECRUITING

American Oncology Partners, Bethesda

34232

RECRUITING

Florida Cancer Specialist & Research Institute Sarasota, Sarasota

37203

ACTIVE_NOT_RECRUITING

SCRI Oncology Partners, Nashville

40536

RECRUITING

University of Kentucky Medical Center MCC-CRO, Lexington

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

53792

RECRUITING

University of Wisconsin Clinical Science Center, Madison

60637

RECRUITING

University of Chicago, Chicago

68130

RECRUITING

Nebraska Methodist Hospital, Omaha

75230

RECRUITING

Mary Crowley Research Center, Dallas

90027

RECRUITING

California Research Institute, Los Angeles

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

92835

RECRUITING

Providence Medical Foundation, Fullerton

07960

WITHDRAWN

Atlantic Health System/Morristown Medical Center, Morristown

Unknown

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

RECRUITING

Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), Hangzhou

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Shanghai East Hospital, Shanghai

RECRUITING

FR33007, Besançon

RECRUITING

Site FR33002, Bordeaux

RECRUITING

FR33008, Paris

RECRUITING

FR33001, Poitiers

RECRUITING

FR33005, Saint-Herblain

RECRUITING

FR33009, Toulouse

RECRUITING

Site FR33004, Villejuif

RECRUITING

National Cancer Center Hospital, Chuo-ku

RECRUITING

Cancer Institute Hospital Of JFCR, Koto-ku

RECRUITING

Site PR1601, Río Piedras

ACTIVE_NOT_RECRUITING

KR82002, Seoul

RECRUITING

Site ES34005, A Coruña, Barcelona

RECRUITING

Site ES34004, Avda

RECRUITING

Site ES34002, Madrid

RECRUITING

ES34008, Málaga

RECRUITING

Site ES34007, Málaga

RECRUITING

Site ES34006, Pozuelo de Alarcón

RECRUITING

ES34003, Santiago de Compostela

464-8681

RECRUITING

Aichi Cancer Center, Chikusa-ku, Nagoya-City

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

241-8515

RECRUITING

Kanagawa Cancer Center, Yokohama

411-8777

RECRUITING

Shizuoka Cancer Center, Sunto-gun

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY